Cerebrovascular safety of sulfonylureas: The role of KATP channels in neuroprotection and the risk of stroke in patients with type 2 diabetes

Diabetes

Volumn 65, Issue 9, 2016, Pages 2795-2809

  Liu, Rui ^a   Wang, Haitao ^a   Xu, Baofeng ^a   Chen, Wenliang ^a   Turlova, Ekaterina ^a   Dong, Nan ^a   Sun, Christopher L F ^a   Lu, Yangqingqin ^a   Fu, Hanhui ^a   Shi, Ranran ^a   Barszczyk, Andrew ^a   Yang, Dongzi ^b   Jin, Tianru ^a   Mannucci, Edoardo ^c   Feng, Zhong Ping ^a   Sun, Hong Shuo ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; DIAZOXIDE; GLYCOGEN SYNTHASE KINASE 3; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; POSTSYNAPTIC DENSITY PROTEIN 95; STREPTOZOCIN; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; DLGH4 PROTEIN, MOUSE; GLYCOGEN SYNTHASE KINASE 3BETA; GUANYLATE KINASE; MEMBRANE PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NR2B NMDA RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD VESSEL; BRAIN DAMAGE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG SAFETY; HUMAN; MALE; META ANALYSIS; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NERVE CELL LESION; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL CULTURE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; IMMUNOHISTOCHEMISTRY; META ANALYSIS (TOPIC); METABOLISM; PHOSPHORYLATION; RISK FACTOR;

ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; GLYCOGEN SYNTHASE KINASE 3 BETA; GUANYLATE KINASES; IMMUNOHISTOCHEMISTRY; KATP CHANNELS; MALE; MEMBRANE PROTEINS; META-ANALYSIS AS TOPIC; MICE; MICE, INBRED C57BL; PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, N-METHYL-D-ASPARTATE; RISK FACTORS; STROKE; SULFONYLUREA COMPOUNDS; TOLBUTAMIDE;

EID: 84987657379     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db15-1737     Document Type: Article

References (68)

1. Kohro T, Yamazaki T, Sato H, et al. Trends in antidiabetic prescription patterns in Japan from 2005 to 2011. Int Heart J 2013;54:93-97
2. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001;37:1053-1059
3. Lukovits TG, Mazzone TM, Gorelick TM. Diabetes mellitus and cerebrovascular disease. Neuroepidemiology 1999;18:1-14
4. Miki T, Nagashima K, Seino S. The structure and function of the ATPsensitive K+ channel in insulin-secreting pancreatic beta-cells. J Mol Endocrinol 1999;22:113-123
5. Noma A. ATP-regulated K+ channels in cardiac muscle. Nature 1983;305: 147-148
6. Ashcroft FM, Harrison DE, Ashcroft SJ. Glucose induces closure of single potassium channels in isolated rat pancreatic beta-cells. Nature 1984;312:446-448
7. Zawar C, Plant TD, Schirra C, Konnerth A, Neumcke B. Cell-type specific expression of ATP-sensitive potassium channels in the rat hippocampus. J Physiol 1999;514:327-341
8. Babenko AP, Aguilar-Bryan L, Bryan J. A view of sur/KIR6.X, KATP channels. Annu Rev Physiol 1998;60:667-687
9. Misler S, Giebisch G. ATP-sensitive potassium channels in physiology, pathophysiology, and pharmacology. Curr Opin Nephrol Hypertens 1992;1:21-33
10. Seino S. ATP-sensitive potassium channels: a model of heteromultimeric potassium channel/receptor assemblies. Annu Rev Physiol 1999;61:337-362
11. Fujimura N, Tanaka E, Yamamoto S, Shigemori M, Higashi H. Contribution of ATP-sensitive potassium channels to hypoxic hyperpolarization in rat hippocampal CA1 neurons in vitro. J Neurophysiol 1997;77:378-385
12. Ashcroft FM. Adenosine 59-triphosphate-sensitive potassium channels. Annu Rev Neurosci 1988;11:97-118
13. Yamamoto S, Tanaka E, Higashi H. Mediation by intracellular calciumdependent signals of hypoxic hyperpolarization in rat hippocampal CA1 neurons in vitro. J Neurophysiol 1997;77:386-392
14. Sun HS, Feng ZP, Miki T, Seino S, French RJ. Enhanced neuronal damage after ischemic insults in mice lacking Kir6.2-containing ATP-sensitive K+ channels. J Neurophysiol 2006;95:2590-2601
15. Sun HS, Xu B, Chen W, et al. Neuronal K(ATP) channels mediate hypoxic preconditioning and reduce subsequent neonatal hypoxic-ischemic brain injury. Exp Neurol 2015;263:161-171
16. Yamada K, Ji JJ, Yuan H, et al. Protective role of ATP-sensitive potassium channels in hypoxia-induced generalized seizure. Science 2001;292:1543-1546
17. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-2471
18. Ferreira BM, Moffa PJ, Falcão A, et al. The effects of glibenclamide, a K (ATP) channel blocker, on the warm-up phenomenon. Ann Noninvasive Electrocardiol 2005;10:356-362
19. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970;19(Suppl.):789-830
20. Goldner MG, Knatterud GL, Prout TE. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. 3. Clinical implications of UGDP results. JAMA 1971;218:1400-1410
21. Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013; 15:938-953
22. Guo G, Kan M, Martinez JA, Zochodne DW. Local insulin and the rapid regrowth of diabetic epidermal axons. Neurobiol Dis 2011;43:414-421
23. Clark WM, Lessov NS, Dixon MP, Eckenstein F. Monofilament intraluminal middle cerebral artery occlusion in the mouse. Neurol Res 1997;19:641-648
24. Turlova E, Bae CY, Deurloo M, et al. TRPM7 regulates axonal outgrowth and maturation of primary hippocampal neurons. Mol Neurobiol 2016;53:595-610
25. Chen W, Xu B, Xiao A, et al TRPM7 inhibitor carvacrol protects brain from neonatal hypoxic-ischemic injury. Mol Brain 2015;8:11
26. Macklis JD, Madison RD. Progressive incorporation of propidium iodide in cultured mouse neurons correlates with declining electrophysiological status: a fluorescence scale of membrane integrity. J Neurosci Methods 1990;31:43-46
27. Tauskela JS, Brunette E, Monette R, Comas T, Morley P. Preconditioning of cortical neurons by oxygen-glucose deprivation: tolerance induction through abbreviated neurotoxic signaling. Am J Physiol Cell Physiol 2003;285:C899-C911
28. Aarts M, Iihara K, Wei WL, et al. A key role for TRPM7 channels in anoxic neuronal death. Cell 2003;115:863-877
29. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010;8:336-341
30. Light RJ, Pillemer DB. Summing Up: The Science of Reviewing Research. Cambridge, Harvard University Press, 1984
31. Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 2006;25: 3443-3457
32. Gore MO, McGuire DK. Cardiovascular disease and type 2 diabetes mellitus: regulating glucose and regulating drugs. Curr Cardiol Rep 2009;11:258-263
33. Mühlhauser I, Sawicki PT, Berger M. Possible risk of sulfonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease. Diabetologia 1997;40:1492-1493
34. McGuire DK, Newby LK, Bhapkar MV, et al.; SYMPHONY and 2nd SYMPHONY Investigators. Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. Am Heart J 2004;147:246-252
35. Policardo L, Seghieri G, Anichini R, et al. Effect of diabetes on hospitalization for ischemic stroke and related in-hospital mortality: a study in Tuscany, Italy, over years 2004-2011. Diabetes Metab Res Rev 2015;31:280-286
36. Li PA, Shuaib A, Miyashita H, He QP, Siesjö BK, Warner DS. Hyperglycemia enhances extracellular glutamate accumulation in rats subjected to forebrain ischemia. Stroke 2000;31:183-192
37. Li PA, Kristián T, Shamloo M, Siesjö K. Effects of preischemic hyperglycemia on brain damage incurred by rats subjected to 2.5 or 5 minutes of forebrain ischemia. Stroke 1996;27:1592-1601; discussion 1601-1602
38. Kagansky N, Levy S, Knobler H. The role of hyperglycemia in acute stroke. Arch Neurol 2001;58:1209-1212
39. Abdelmoneim AS, Eurich DT, Light PE, et al. Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer. Diabetes Obes Metab 2015;17:523-532
40. Niethammer M, Kim E, Sheng M. Interaction between the C terminus of NMDA receptor subunits and multiple members of the PSD-95 family of membrane-associated guanylate kinases. J Neurosci 1996;16:2157-2163
41. Shu S, Pei L, Lu Y. Promising targets of cell death signaling of NR2B receptor subunit in stroke pathogenesis. Regen Med Res 2014;2:8
42. Chen G, Bower KA, Ma C, Fang S, Thiele CJ, Luo J. Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death. FASEB J 2004;18:1162-1164
43. Betourne A, Bertholet AM, Labroue E, et al. Involvement of hippocampal CA3 K(ATP) channels in contextual memory. Neuropharmacology 2009;56: 615-625
44. Johansen FF. Interneurons in rat hippocampus after cerebral ischemia. Morphometric, functional, and therapeutic investigations. Acta Neurol Scand Suppl 1993;150:1-32
45. Lipton P. Ischemic cell death in brain neurons. Physiol Rev 1999;79:1431-1568
46. Stegmayr B, Asplund K. Diabetes as a risk factor for stroke. A population perspective. Diabetologia 1995;38:1061-1068
47. Thom T, Haase N, Rosamond W, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006;113:e85-e151
48. Chukwuma C Sr, Tuomilehto J. Diabetes and the risk of stroke. J Diabetes Complications 1993;7:250-262
49. Towfighi A, Saver JL. Stroke declines from third to fourth leading cause of death in the United States: historical perspective and challenges ahead. Stroke 2011;42:2351-2355
50. Bruno A, Kent TA, Coull BM, et al. Treatment of hyperglycemia in ischemic stroke (THIS): a randomized pilot trial. Stroke 2008;39:384-389
51. Arrick DM, Sun H, Mayhan WG. Influence of exercise training on ischemic brain injury in type 1 diabetic rats. J Appl Physiol (1985) 2012;113:1121-1127
52. Arechavaleta R, Seck T, Chen Y, et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2011;13:160-168
53. Bakris GL, Ruilope LM, Mcmorn SO, et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens 2006;24:2047-2055
54. Charbonnel B, Roden M, Urquhart R, et al. Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens. Diabetologia 2005;48:553-560
55. Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009; 11:157-166
56. Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet 2012;380:475-483
57. Gerstein HC, Ratner RE, Cannon CP, et al.; APPROACH Study Group. Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the Assessment on the Preventionof Progression by Rosiglitazone on Atherosclerosis in Diabetes Patients With Cardiovascular History trial. Circulation 2010;121:1176-1187
58. Göke B, Gallwitz B, Eriksson J, Hellqvist A, Gause-Nilsson I; D1680C00001 Investigators. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J of Clin Pract 2010;64:1619-1631
59. Home PD, Pocock SJ, Beck-Nielsen H, et al.; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373:2125-2135
60. Hong J, Zhang YF, Lai SH, et al.; SPREAD-DIMCAD Investigators. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care 2013;36:1304-1311
61. Kahn SE, Haffner SM, Heise MA, et al.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J of Med 2006;355:2427-2443
62. Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev 2005;21:167-174
63. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006;296:2572-2581
64. Nissen SE, Nicholls SJ, Wolski K, et al.; PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008;299:1561-1573
65. Riddle MC, Schneider J. The Climepiride Combination Group. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Diabetes Care 1998;21:1052-1057
66. Sullivan D, Forder P, Simes J, et al.; FIELD Study Investigators. Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study. Diabetes Res Clin Pract 2011;94:284-290
67. Tolman KG, Freston JW, Kupfer S, Perez A. Liver safety in patients with type 2 diabetes treated with pioglitazone results from a 3-year, randomized, comparator-controlled study in the US. Drug Saf 2009;32:787-800
68. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). [published correction appears in Lancet 1999;354:602]. Lancet 1998;352:837-853